5 Results for "

CB17 SCID mice

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "CB17 SCID mice" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-148152A
Purity:  98.15%
Target:  

PSMA

Research Areas:  

Cancer

PSMA I&S TFA is a PSMA-targeted imaging agent. PSMA I&S TFA undergoes PSMA-mediated internalization into PSMA-expressing cells, with uptake into PSMA-positive tissues competitively inhibited by a potent PSMA inhibitor. PSMA I&S TFA can be used for the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-158113
CAS No.: 3037549-86-0
Research Areas:  

Cancer

CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC50 of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC50s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .
loading...
    loading...
Cat. No.: HY-174129
CAS No.: 2649008-95-5
Target:  

Btk Apoptosis

Research Areas:  

Cancer

TM471-1 is an orally active and covalent Bruton's tyrosine kinase (BTK) inhibitor with IC50 values of 1.3 nM (BTK WT), >40,000 nM (BTK C481S), 7.9 nM (TEC) and 12.4 nM (TXK). TM471-1 inhibits cell growth in vivo and in vitro, arrests cell cycle at G0/G1 phase and induces cell apoptosis .
loading...
    loading...
Cat. No.: HY-182793
CAS No.: 3058433-50-1
Research Areas:  

Cancer

MLL1-IN-1 is an orally active MLL1 inhibitor with an IC50 of 0.043 μM. MLL1-IN-1 induces Menin protein degradation and inhibits the proliferation of leukemia cells. MLL1-IN-1 can induce tumor regression in leukemia-bearing mice. MLL1-IN-1 is useful for research into MLL1-associated leukemia .
loading...
    loading...
Cat. No.: HY-183031
CAS No.: 3059866-62-2
Research Areas:  

Cancer

BrAA-glycine-BG-PAB-Exatecan (Compound LD-11) is an Drug-Linker Conjugates for ADC, consisting of Exatecan (HY-13631) and a linker. BrAA-glycine-BG-PAB-Exatecan can be conjugated with anti-ROR1 antibodies to form an ADC .
loading...
    loading...